Press Release Sep 13 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the receipt of final approval from the USFDA for Lenalidomide Capsules in multiple strengths. The approval includes final permissions for several strengths and tentative approvals for others, indicating the company's expansion in oncology therapies. The drug is intended for treating various cancers and certain blood disorders, and will be manufactured in Ahmedabad, India. The company aims to enhance access to affordable medication in the US market with this approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 12 2022
- Press Release Sep 09 2022
- Press Release Sep 07 2022
- Press Release Aug 31 2022
- Press Release Aug 30 2022
Later from Zydus Lifesciences
- Press Release Sep 16 2022
- Press Release Sep 20 2022
- Press Release Oct 01 2022
- Press Release Oct 03 2022
- Press Release Oct 04 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences